Bifidobacterium longum subsp. infantis

Literature and Product Labels#

WikiBiome preserves “B. infantis” or “Bifidobacterium infantis” when a cited paper or product formulation used that historical or shorthand label. Such wording does not establish that an incompletely identified formulation contained the current subspecies.

The thyroidectomy probiotic trial, the VSL#3 hypothyroidism trial, and the five-strain case report each used an infantis label without providing enough strain-level taxonomic evidence in the WikiBiome source record to independently assign that component to NCBITaxon:1682.^{[4]Lin 2022 — Probiotics alleviate oral-gut microbiota dysbiosis in thyroid cancer patients after thyroidectomy: RCTBaiqiang Lin, Fuya Zhao, Yang Liu et al. · 2022Open reference 4 ↓[5]Spaggiari 2017 — Probiotics (VSL#3) do not directly affect thyroid hormonal parameters in levothyroxine-treated hypothyroid patientsGiorgia Spaggiari, Giulia Brigante, Sara De Vincentis et al. · 2017Open reference 5 ↓[6]Griffith 2026 — Lifestyle Changes and Probiotic Supplementation for Improving Longstanding Type 2 Diabetes in a Male Undergoing Testosterone Replacement TherapyAnna Griffith, Adam Perlman, Tara Karr et al. · 2026Open reference 6 ↓}

Strain Boundary#

Strain 35624 must not be treated as evidence for this subspecies. Although older clinical literature called it “B. infantis 35624,” comparative core-genome analysis assigned it to Bifidobacterium longum subsp. longum.^{[7]Genome Analysis and Characterisation of the Exopolysaccharide Produced by Bifidobacterium longum subsp. longum 35624Friedrich Altmann, Paul Kosma, Amy O'Callaghan et al. · 2016Open reference 7 ↓}

Clinical findings reported under the historical label remain findings about strain 35624; they do not transfer to NCBITaxon:1682 or to other strains bearing an infantis label.

Cross-References#

• Bifidobacterium longum—parent species
• Bifidobacterium—genus page
• Bifidobacteriaceae—family context